These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20494468)

  • 1. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.
    Yu PC; Bosnyak Z; Ceriello A
    Diabetes Res Clin Pract; 2010 Jul; 89(1):1-9. PubMed ID: 20494468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
    Giugliano D; Ceriello A; Razzoli E; Esposito K
    Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes.
    Woo V; Shestakova MV; Ørskov C; Ceriello A
    Int J Clin Pract; 2008 Dec; 62(12):1935-42. PubMed ID: 19166440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
    Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
    Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.
    Monnier L; Colette C; Owens DR
    Diabetes Metab Res Rev; 2009 Jul; 25(5):393-402. PubMed ID: 19437415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
    Cavalot F
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megatrials in type 2 diabetes. From excitement to frustration?
    Del Prato S
    Diabetologia; 2009 Jul; 52(7):1219-26. PubMed ID: 19373446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
    Bonora E
    Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
    Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
    Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes.
    Peter R; Dunseath G; Luzio SD; Chudleigh R; Choudhury SR; Owens DR
    Diabet Med; 2009 Oct; 26(10):974-80. PubMed ID: 19900228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
    Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
    Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.
    Zhou JJ; Coleman R; Holman RR; Reaven P
    Diabetologia; 2020 Nov; 63(11):2482-2485. PubMed ID: 32954444
    [No Abstract]   [Full Text] [Related]  

  • 19. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes.
    Brown SH; Abdelhafiz AH
    Postgrad Med; 2009 Sep; 121(5):31-41. PubMed ID: 19820272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.